Pharmacyclics (PCYC) Tops Q1 EPS by 32c, Revenue Misses

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CRWD
6. CHKP
7. ON
8. HNGE
9. INSP
10. AMD

Go back to Pharmacyclics (PCYC) Tops Q1 EPS by 32c, Revenue Misses

Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates

May 1, 2015 9:15 AM EDT

SUNNYVALE, Calif., May 1, 2015 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter ended March 31, 2015, as well as general business updates. Due to the pending merger with AbbVie Inc., no conference call will be held.

Key Highlights

Total revenue for the quarter ended March 31, 2015 increased to $206 million from $119 million for the quarter ended March 31, 2014. Worldwide IMBRUVICA® (ibrutinib) net product revenue of $247 million was earned for the quarter ended March 31, 2015, including $58 million of total ex-U.S. product... More